Conclusiones

La imagen de difusión es una herramienta no invasiva poderosa que aporta información cuantitativa y cualitativa acerca de la celularidad tumoral y la estructura tisular del CP y permite la detección tumoral y la estadificación del CP. La combinación pretratamiento del valor de ADC tumoral, score Gleason y el PSA basal puede  jugar un importante papel en la estadificación del grupo de riesgo para el tratamiento del CP, que podría mejorar el control del carcinoma durante el tratamiento reduciendo el riesgo de complicaciones secundarias.

La secuencia de difusión ayuda a localizar el tumor en pacientes con biopsia transrectal negativa y permite monitorizar los efectos del tratamiento radioterápico o/y hormonal del CP.

El uso de la imagen de difusión junto con las imágenes T2 mejoran la detección de recurrencia local tras prostatectomía radical, radioterapia u hormonoterapia  y facilita la detección de adenopatías metastásicas y metástasis hematógenas (hueso e hígado).

BIBLIOGRAFÍA

1. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR 2007; 188:1622–1635.
2. Le Bihan D. Diffusion/perfusion MR imaging of the brain: from structure to function. Radiology 1990; 177:328–329.
3.  Jacobs MA, Ibrahim TS, Ouwerkerk R. AAPM/RSNA Physics Tutorial for Residents: MR imaging: brief overview and emerging applications. Radiographics 2007; 27(4):1213-29.
4. Poustchi-Amin M, Mirowitz SA, Brown JJ, McKinstry RC, Li T. Principles and applications of echo-planar imaging: a review for the general radiologist. Radiographics 2001;21(3):767-79.
5. Koh D, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007;188(6):1622-35.
6. Stejskal E, Tanner J. Spin diffusion measurements: spin echoes in presence of a time-dependent field gradient. J Chem Phys 1965;42:288.
7. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010; 25.
8. Hagmann P, Jonasson L, Maeder P, Thiran JP, Wedeen VJ, Meuli R. Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. Radiographics 2006; 26:S205-S223. 4(1):47-66.
9. Poustchi-Amin M, Mirowitz SA, Brown JJ, McKinstry RC, Li T. Principles and applications of echo-planar imaging: a review for the general radiologist. Radiographics 2001; 21(3):767-79.
10.  Neil JJ. Measurement of water motion (apparent diffusion) in biological systems. Concepts Magn Reson 1997; 9(6):385-401.
11.  desouza NM, Reinsberg SA, Scurr ED, Brewster JM, Payne GS. Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol 2007;80(950):90–95.
12. Le Bihan D, Poupon C, Amadon A, Lethimonnier F. Artifacts and pitfalls in diffusion MRI. J Magn Reson Imaging 2006;24(3):478–488.
13. American Cancer Society. Prostate cancer facts. In: Cancer facts & figures 2009. Atlanta, Ga: American Cancer Society, 2009; 19–20.
14. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350(22):2239–2246.
15. 15. Basso D, Fogar P, Piva MG, et al. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when? Urology 2000;55(5):710–715.
16. Park BK, Lee HM, Kim Ck,Choi HY, ParK JW. Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. Invest Radiol. 2008;43(11):789-93.
17. Kim JH,Kim JK,Park BW, Kim N,Cho KS.Apparent diffusion coefficient: prostate cancer versus noncancerous tissue according to anatomical region. J Magn Reson Imaging. 2008;28(5):1173-9.
18. Baris TurKbey B,Shah VP, Pang Y et al. Is Apparent Diffusion Coefficient Associated with Clinical Risk Scores for Prostate Cancers that Are Visible on 3-T MR Images?. Radiology 2011;258:488-495).
19. Barentsz JO, Richenberg J, Clements R, et al.ESUR prostate MR guidelines 2012. Eur Radiol 2012; DOI 10.1007/s00330-011-2377-y.
20. Kim CK, Park BK, Lee HM, Kwon GY. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol 2007; 42:842–847.
21. Kim CK,Choi D, Park BK, Kwon GY, Lim HK.Diffusion-weighted MR imaging for the evaluation of seminal vesicle invasion in prostate cancer: initial results. J. Magn Reson imaging.2008;28(4):963-9.
22. Hovels AM, Heesakkers RA, Adang EM, Barentsz JO, Jager GJ, Severens JL. Cost-effectiveness of MR lymphography for the detection of lymph node metastases in patients with prostate cancer. Radiology. 2009;252:729–36.
23. Behesthi M,Imamovic L, Broinger G, et al.F18 FCholine PET/CT in the Preoperative Staging of Prostate Cancer in Patients with Intermediate or High Risk of Extracapsular Disease: A Prospective Study of  130 Patients 1. Radiology. Mar;254(3):925-33.
24. Barcelo J, Vilanova JC, Riera E,et al. Resonancia magnética de todo el cuerpo con técnica de difusión (PET virtual) para el cribado de las metástasis óseas. Radiología.2007;49:407–15.
25. Hajihara H, Hayasshida Y, Murakani R, et al.Usefulness of diffusion-weighted imaging in the localization of prostate cancer.Int J Radiat, Oncol Biol Phys. 2009;74(2):399-403.
26. Son I, Kim CK, Park BK, Park W. Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T. Am J Roentgenol. 2010 ;195:477-482.
27. 27. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.Int J Radiat, Oncol Biol Phys.2006;65(4):965-74.
28. Kim CK, Park BK, Lee HM. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 2009; 29:391–397.
29. Rosser C.; Kuban D.; levy l, . et al. Prostate specific antigen bounce phenomenon af­ter external beam radiation for clinically localized prostate cancer. J Urol.2002 Nov;168(5):2001-5.
30. Hanlon A, Pinover W, Horwitz E, et al. Patterns and fate of PSA bouncing follo­wing 3DCRT. Int. J. Radiat Oncol  Biol  Phys 2001, 55: 845-9.
31. Schmid DT, John H, Zweifel  R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology,2005; 235: 623-8.
32. Xu J, Humphrey PA, Kibel AS, et al.Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. Magn Reson Med 2009;61:842–850.
33. Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 2006; 6:135–143.
34. Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008;28(3):720–726.
35. Lim HK, Kim JK, Kim KA, Cho KS.) Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection–a multireader study. Radiology 2009;250:145–151.
36. Yoshimitsu K, Kiyoshima K, Irie H, et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging 2008;27:132–139.